DYAX CORP Sample Clauses

DYAX CORP. By: By: Name: Name: Title: Title: Address: Facsimile: ATTACHMENT A PAYMENT SCHEDULE ----------------------------------------------------------------- PAYMENTS ----------------------------------------------------------------- Signing Fee $ 52,500 ----------------------------------------------------------------- Annual Maintenance Fee $ 27,500 ----------------------------------------------------------------- Each transfer of one or more Licensed $ 27,500 Intermediates or provision of services therefor for a specific target ----------------------------------------------------------------- First application for a 510(k), PMA or $ 102,500 equivalent for each indication ----------------------------------------------------------------- Royalty rate on Net Sales 2.2% ----------------------------------------------------------------- Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions. ATTACHMENT B PATENT RIGHTS ========================================================================================================= APPLICATION/ COUNTRY PATENT NO. FILING DATE PATENT NO. ISSUE DATE --------------------------------------------------------------------------------------------------------- US 07/664,989* 3/1/91 5,223,409 6/29/93 --------------------------------------------------------------------------------------------------------- US 9,319 1/26/93 5,403,484 4/4/95 --------------------------------------------------------------------------------------------------------- US 08/057,667 6/18/93 5,571,698 11/5/96 --------------------------------------------------------------------------------------------------------- US div 08/415,922 4/3/95 5,837,500 11/17/98 --------------------------------------------------------------------------------------------------------- US div 08/993,776 12/18/97 --------------------------------------------------------------------------------------------------------- US div ************* 11/16/98 --------------------------------------------------------------------------------------------------------- US div ************* 11/16/98 --------------------------------------------------------------------------------------------------------- PCT US89/03731 9/1/89 W09002809 pub 3/22/90 --------------------------------------------------------------------------------------------------------- EPO 89/910702.3 9/1/89 436,597 4/2/97 EP436597 pub 7/17/91 ----------------------------------...

DYAX CORP. BY: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇ ------------------------------------------ ▇▇▇▇▇ ▇. ▇▇▇▇▇ Chairman and Chief Executive Officer HUMAN GENOME SCIENCES, INC. BY: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ------------------------------------------ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ Senior Vice President, Corporate and Business Development Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions. EXHIBIT A Patent Rights ================================================================================ Application/ Country Patent No. Filing Date Patent No. Issue Date ------- ---------- ----------- ---------- ---------- -------------------------------------------------------------------------------- US 07/664,989* 3/1/91 5,223,409 6/29/93 -------------------------------------------------------------------------------- US 9,319 1/26/93 5,403,484 4/4/95 -------------------------------------------------------------------------------- US 08/057,667 6/18/93 5,571,698 11/5/96 -------------------------------------------------------------------------------- US div 08/415,922 4/3/95 5,837,500 11/17/98 -------------------------------------------------------------------------------- US div 08/993,776 12/18/97 -------------------------------------------------------------------------------- US div ************* 11/16/98 -------------------------------------------------------------------------------- US div ************* 11/16/98 -------------------------------------------------------------------------------- PCT US89/03731 9/1/89 W09002809 pub 3/22/90 -------------------------------------------------------------------------------- EPO 89/910702.3 9/1/89 436,597 4/2/97 EP436597 pub 7/17/91 -------------------------------------------------------------------------------- EPO div 96/112867.5 8/9/96 Allowed ************* 4/16/97 pub -------------------------------------------------------------------------------- Japan ▇▇▇▇▇▇▇▇ 9/1/89 JP4502700 (pub) 5/21/92 -------------------------------------------------------------------------------- Canada 610,176 9/1/89 1,340,288 12/29/98 -------------------------------------------------------------------------------- Ireland IR89/2834 9/4/89 -------------------------------------------------------------------------------- ▇▇▇▇▇▇ ▇▇▇▇▇ 9/1/89 91501 6/11/98 -------------------------------------------------------------------------------- Israel ************* 5/29/97 ---------------------------------------------------------...

DYAX CORP. By: By: Name: Name: Title: Title: Address: Facsimile: ATTACHMENT A PAYMENT SCHEDULE ----------------------------------------------------------------- PAYMENTS ----------------------------------------------------------------- Signing Fee $ 52,500 ----------------------------------------------------------------- Annual Maintenance Fee $ 27,500 ----------------------------------------------------------------- Each transfer of one or more Licensed $ 27,500 Intermediates or provision of services therefor for a specific target ----------------------------------------------------------------- First application for a 510(k), PMA or $ 102,500 equivalent for each indication ----------------------------------------------------------------- Royalty rate on Net Sales 2.2% -----------------------------------------------------------------

DYAX CORP a Delaware corporation (the "Company"), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the "Underwriters"), acting severally and not jointly, for which Furm▇▇ ▇▇▇▇ ▇▇▇ and Pacific Growth Equities, Inc. are acting as representatives (the "Representatives"), an aggregate of 2,500,000 of the Company's Common Shares, $0.01 par value per share (the "Common Shares"). The 2,500,000 Common Shares to be purchased by the Underwriters are referred to herein as the "Initial Shares." The Company also proposes to issue and sell to the several Underwriters, acting severally and not jointly, an aggregate of not more than 375,000 additional Common Shares (the "Additional Shares"), if requested by the Underwriters in accordance with Section 4 hereof. The Initial Shares and the --------

DYAX CORP. Materials Transfer Agreement between Dyax Corp. and Lumera Corporation, entered in as of June 20, 2007

DYAX CORP. By: /s/ I▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇ Name: I▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇ Title: Executive Vice President and General Counsel